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to chronic inflammatory diseases (rheuma-
toid arthritis, inflammatory bowel diseases) 
[3], chronic infections and neoplasms such 
as Hodgkin lymphoma and renal cell carci-
noma [4]. AL amyloidosis is the most com-
mon type of systemic amyloidosis. Clinical 
presentation of AL amyloidosis is characte-
rized by vague and non-specific symptoms. 
The organs frequently affected are kidney, 
heart, liver, autonomic nervous system, soft 
IntroduCtIon
Amyloidosis is a pathologic diagnosis 
characterized by extracellular deposition 
of insoluble protein fibrils in various or-
gans and tissues. These proteins possess the 
ability to bind Congo red stain and appe-
ar apple-green under polarized light [1,2]. 
There are two main forms of amyloidosis, 
primary amyloidosis (AL) and secondary 
amyloidosis (AA). AL amyloidosis is cha-
racterized by deposition of immunoglobulin 
light chains or their fragments, produced 
by a clonal population of plasma cells in 
the bone marrow as is in multiple myeloma 
(MM), monoclonal gammopathy of unde-
termined significance (MGUS) and others 
plasma cells disorders. AA is characterized 
by deposition of amyloid in tissues secondary 
Why we describe this case
A surgical problem hid a hematological/
internal medicine diagnosis. Therefore a 
multidisciplinary management is very 
important to make the correct diagnosis
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Case report
Abstract
Amyloidosis is a pathologic diagnosis characterized by extracellular deposition of insoluble 
protein fibrils in various organs and tissues. There are two main forms of amyloidosis, primary 
amyloidosis, and secondary amyloidosis. Gastrointestinal involvement is common in both 
amyloidosis forms. 
We describe the case of a 78-year-old woman taken to the operating room for small bowel 
obstruction, found to have pseudo-obstruction and enteritis. Exploratory laparotomy revealed 
gastric mass and histological examen showed extensive amyloid deposition consistent with 
amyloidosis. Hematological evaluation revealed unknown multiple myeloma. This case report 
and literature data suggest to perform a hematological examination in patients with amyloidosis 
diagnosis to exclude a multiple myeloma or other plasma cell disorders. 
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Amiloidosi sistemica dovuta a mieloma multiplo sconosciuto in paziente con pseudo-ostruzione 
intestinale: segnalazione di un caso 
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tissues, therefore the suspect diagnosis of 
AL amyloidosis should be considered in 
patients with proteinuria, cardiomyopathy, 
neuropathy, hepatomegaly, macroglossia, en-
docrinopathies [5]. Gastrointestinal involve-
ment is common in AL (70% of cases) and 
AA (55% of cases) amyloidosis [6]. Systemic 
amyloidosis is a rare disease and the patients 
often present non-specific gastrointestinal 
symptoms: abdominal pain, gastrointestinal 
bleeding, pseudo-obstruction, diarrhea [3,7]. 
AL amyloidosis diagnosis requires biopsy 
demonstration of amyloid deposits in tis-
sues and particularly in periumbilical fat [8] 
and demonstration of plasma cell dyscrasia 
with bone marrow biopsy, electrophoresis 
and immunofixation in the serum and uri-
ne; additionally serum free light chain assay 
is important in diagnosis, monitoring and 
prognosis of AL amyloidosis [9].
We report a case of AL amyloidosis with 
gastric and small bowel involvement on a 
patient who was unknown MM.
CASe report
A 78-year-old woman was admitted to our 
hospital on September 2014 with a history 
of abdominal pain and clinical signs of in-
testinal occlusion.
Laboratory tests showed a mild normo-
chromic normocytic anemia, a reduction of 
total proteins and cholinesterases (Table I).
Electrocardiography showed voltage re-
duction in all derivations; CT scan abdomen 
showed dilatation of small bowel with me-
senteric edema and the patient was taken to 
the operating room.
Laparotomy exploratory revealed a dilata-
tion of small bowel with mesenteric edema 
by pseudo-obstruction and gastric mass su-
spected to be of neoplastic etiology. Partial 
gastrectomy was performed and patient was 
referred in chirurgic division. Histological 
examination showed deposition of eosino-
philic material in gastric mucosa, submuco-
sa and muscularis mucosae. The deposit had 
an apple-green birefringence by Congo red 
stain under polarized light. The diagnosis of 
amyloidosis was made. Periumbilical fat biop-
sy confirmed systemic amyloidosis diagnosis.
Hematologists were consulted and various 
examinations were executed, revealing the 
presence in urine of Bence Jones protein–k 
chains (Table II). Serum protein electropho-
resis showed hypogammaglobulinemia, no 
monoclonal component (Table III), while 
bone marrow fine-needle aspiration show-
ed plasmacellular involvement rate in 40% 
of total cells.
The final diagnosis was therefore a MM 
and systemic AL. Chemotherapy protocol 
VMP (bortezomib, melphalan, prednisone) 
was programmed but the patient died by 
cardiac failure, few days after MM diagnosis, 
before the therapy was started.
parameter Values detected normal values
Hemoglobin (g/dl) 11.6 12-17
Total proteins (g/dl) 5.4 6.4-8.3
Cholinesterases (UI/L) 3890 4,700-14,000
table I. First laboratory 
tests: main results
parameter Values detected normal values
Bence Jones protein–k chains Present Absent
IgG-K/urine (mg/l) 2570 0-10
IgG-L/urine (mg/l) 10.4 0-5
Ratio K/L 247.1 0.7-6.2
table II. Urine tests: 
main results
parameter Values detected normal values
Gammaglobulin (g/dl) 0.22 0.80-1.35
IgG (g/l) 3 7-16
IgA (g/l) 0.5 0.7-4
IgM (g/l) 4.0 0.4-2.3
Beta2-microglobulin (mg/l) 2.4 0.2-2.3
table III. Serum protein 
electrophoresis: main 
results
To suspect in patient with amyloidosis a MM
We suggest to make a hematological examination in patients with amyloidosis diagnosis to 
exclude a MM or others plasma cell disorders; bone marrow fine-needle aspiration to make 
indispensable although monoclonal gammopathy absence
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dISCuSSIon
AL amyloidosis rarely presents without 
systemic symptoms. The kidneys and heart 
are often involved, but the nervous system, 
lungs, liver, soft tissue and gastrointestinal 
tract can be involved. Gastrointestinal in-
volvement is common in AL (70% of ca-
ses) and AA (55% of cases) amyloidosis [6]. 
Pseudo-obstruction have been described in 
few patients with AL and AA amyloido-
sis [10,11]. Intestinal pseudo-obstruction 
is characterized by symptoms and signs of 
mechanical obstruction in the absence of any 
organic occlusion of the lumen.
We report a case of small bowel pseudo-
obstruction secondary to AL amyloidosis 
in patient with unknown MM. Intestinal 
pseudo-obstruction is caused by amyloid 
deposition in muscular or nervous tissue of 
gastrointestinal tract causing myopathy or 
neuropathy, respectively [10].
AL amyloidosis is often associated with 
MM, smoldering multiple myeloma, MGUS 
[12].
About 10% of AL patients may have MM 
at the time of diagnosis and 30% of MM 
patients may have amyloid deposition at 
the time of diagnosis [13]. A patient with 
myeloma may have or develop AL amyloi-
dosis, but it is rare for a patient with AL 
amyloidosis, who does not have myeloma at 
presentation, to progress in myeloma. In this 
case report the patient received occasionally 
diagnosis of amyloidosis and, after hemato-
logical examinations, a unknown MM was 
diagnosed.
The intestinal obstruction was the first 
symptom of AL in a patient who had a MM 
probably for some time and who subsequen-
tly developed amyloidosis. As reported in the 
literature [7,8], the onset of amyloidosis in 
a patient with MM is much more common 
than the contrary.
Early diagnosis and identification of the 
type of amyloidosis are critical in the care of 
patients with this disease, to allow the rever-
sal of organ damage and a better tolerability 
of adverse effects of therapy.
In conclusion, this case report and litera-
ture data suggest to perform a hematological 
examination in patients with amyloidosis 
diagnosis to exclude a MM or other plasma 
cell disorders; furthermore the importance of 
a multidisciplinary approach to the amyloi-
dosis is confirmed.
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